U.S. Markets closed

Alnylam Pharmaceuticals: Multiple Near-Term Catalysts

Kenneth Smith
Alnylam Pharmaceuticals: Multiple Near-Term Catalysts

Alnylam Pharmaceuticals (ALNY), a biopharmaceutical company focused on developing novel therapeutics based on RNA (ribonucleic acid) interference, delivered robust top line growth in the second quarter. It reported its second-quarter results on August 2.